**Abstract**

**Background:** Preliminary results have supported the use of D-cycloserine (DCS), a partial agonist at theN-methyl-D-aspartate receptor in the amygdala,to augment exposure therapy in adult anxiety disorders; however, no data have been provided a quantitative review of DCS-augmented cognitive behavioral therapy literature.

**Objectives:** To investigate the effect of DCS enhances the overall efficacy of cognitive-behavioral therapy (CBT) inthe treatment of obsessive-compulsive disorder (OCD).

**Methods:** Medline/Pubmed, OVID,and the Cochrane central register of controlled trialswere searched through to May 2015. Five of the 338 articles (n = 119 participants) initiallyidentified met the inclusion criteria, reporting 5 randomized controlled trials.

**Results:** Compliance with homogeneity, effect of each literature can be combined using a fixed effect model (Chi^2^=2.97, i^2^=0%, p=0.56). The confidence interval of most studies crossesthe vertical line of null effect (mean difference equal to zero),indicating that the majority of these studies did not find astatistically significant difference between DCS+CBT and placebo+CBT.

**Conclusions:** D-cycloserine has a neutral effect on enhancingcognitive-behavioral therapy in the treatment of obsessive compulsive disorder in randomized controlled trials. The present results fail to support the use of D-cycloserine with cognitive behavioral therapy for obsessive compulsive disorder.
